• Shopping cart is empty.

    The International Society for Aerosols in Medicine

    Otmar Schmid

    Otmar Schmid

    Dr. Otmar Schmid

    Helmholtz Zentrum München

    Dr. Schmid is head of the Pulmonary Aerosol Delivery Group at the Comprehensive Pneumology Center & Helmholtz Zentrum München (Munich, Germany) and Adjunct Assistant Professor at the Missouri University of Science and Technology (Rolla, MO, USA). His research interests include

    • • dose-controlled aerosolized drug delivery to in vitro and in vivo models of the lung
    • • development of advanced bioreactors of the lung
    • • preclinical whole lung imaging for deposition, biokinetics and cellular targeting of nanocarriers
    • • in vitro/in vivo/clinical correlation

    He is co-inventor of the patented ALICE-CLOUD technology for dose-controlled aerosol exposure of in vitro air-liquid cell models, which is commercially available as VITROCELL CLOUD system (VITROCELL Systems, Germany). He has served on the ISAM board, as chair of ISAM Networking Groups and as co-organizer of ISAM symposiums.

    Advanced in vitro and in silico models improve predictions of in vivo/clinical pharmacokinetics of nanocarrier-laden inhaled drugs

    Determination of the pharmacokinetics (PK) profile of inhaled drugs is an important part of clinical drug testing. Current in vitro testing strategies for lung deposition and absorption prediction often rely on impactor measurements and membrane-based, cell-free perfusion modules. While these cell-free in vitro methods have been widely used, quantitative predictions of exact PK profiles of novel drugs is still elusive. In this presentation evidence is shown that air-liquid cell culture models in combination with in silico models of aerosol lung deposition and physiologically-based, pharmacokinetics (PBPK) are capable of quantitative prediction of the PK profile. This is demonstrated for nanocarrier-laden drugs (e.g. liposomes) using empirically observed PK profiles in animals and humans for validation.